Drinking levels (binge, volume) and alcohol consequences: using national data to identify clinical trial endpoints - Administrative Supplement

饮酒水平(酗酒、饮酒量)和酒精后果:使用国家数据确定临床试验终点 - 行政补充

基本信息

项目摘要

PROJECT SUMMARY In the project, “Drinking Levels (Binge, Volume) And Alcohol Consequences: Using National Data To Identify Clinical Trial Endpoints” (R01AA025309), epidemiologic data have been used to investigate the relationship of heavy drinking indicators to the risk for alcohol dependence and other drinking consequences. Much of the work for this study has focused on whether non-abstinent drinking reductions improve how individuals feel and function across a broad range of domains. In the project, drinking reduction has primarily been measured by the World Health Organization (WHO) risk drinking levels: very high risk, high risk, moderate risk, and low risk. These represent gender-specific average volumes of ethanol consumed per day. Health outcomes have covered a broad range of domains, including alcohol dependence (occurrence, persistence), impaired functioning, liver disease, AUDIT-C screening scores, drug use disorders, depressive/anxiety disorders, and cardiovascular disease. The project has also contributed to papers addressing similar issues regarding WHO risk drinking levels in treatment data from randomized clinical trials. However, the study did not include the relationship of WHO risk drinking levels to additional important variables that are often highly related to drinking levels and also to the outcomes already analyzed. In particular, these additional variables include tolerance to alcohol; family history of alcohol use disorders; and sexual minority status. In addition, no information exists on whether experiencing discrimination as a member of a sexual minority group moderates the relationship of sexual minority status to WHO risk drinking levels. Therefore, Aim 1 of this administrative supplement is to conduct these additional analyses on WHO risk drinking levels and alcohol tolerance, family history of alcohol use disorders, and sexual minority status, which will involve unanticipated costs. Furthermore, no document exists that summarizes extant information on the epidemiology of heavy drinking and alcohol use disorders (AUD), including the findings of the project, in a user-friendly form for healthcare providers. Healthcare providers are often not knowledgeable about the epidemiology of heavy drinking and AUD and the benefits of non-abstinent drinking reduction. Providing this knowledge to them may help them do improved screening and brief interventions with their patients. Therefore, Aim 2 of this administrative supplement is to prepare a document for healthcare providers that summarizes accurate knowledge about the epidemiology of heavy drinking and alcohol use disorders in a manner that will be easy for the healthcare providers to understand and use. This work will also involve unanticipated costs.
项目概要 在该项目中,“饮酒水平(酗酒、饮酒量)和酒精后果:使用国家数据来识别 临床试验终点”(R01AA025309),流行病学数据已被用来调查以下关系: 酗酒指标表明酒精依赖和其他饮酒后果的风险。大部分工作 这项研究的重点是非戒酒减少是否会改善个人的感觉和功能 跨越广泛的领域。在该项目中,饮酒减少量主要通过世界各地来衡量 卫生组织 (WHO) 风险饮酒水平:极高风险、高风险、中度风险和低风险。这些 代表特定性别每天消耗的平均乙醇量。健康成果涵盖了 广泛的领域,包括酒精依赖(发生、持续)、功能受损、肝脏 疾病、AUDIT-C 筛查评分、药物使用障碍、抑郁/焦虑障碍和心血管疾病 疾病。该项目还撰写了一些论文,讨论有关世界卫生组织风险饮酒水平的类似问题 来自随机临床试验的治疗数据。然而,该研究并未包括世界卫生组织风险之间的关系 饮酒水平涉及其他重要变量,这些变量通常与饮酒水平高度相关,也与 结果已经分析过了。特别是,这些额外的变量包括对酒精的耐受性;家史 酒精使用障碍;和性少数地位。此外,没有关于是否经历过的信息 作为性少数群体成员的歧视会缓和性少数地位与性少数群体的关系 世界卫生组织风险饮酒水平。因此,本行政补充文件的目标 1 是进行这些额外的 对世界卫生组织风险饮酒水平和酒精耐受性、酒精使用障碍家族史以及性行为的分析 少数地位,这将带来意想不到的成本。此外,没有任何文件总结现有的 有关重度饮酒和酒精使用障碍 (AUD) 流行病学的信息,包括调查结果 项目,以医疗保健提供者用户友好的形式。医疗保健提供者往往不了解 大量饮酒和澳元的流行病学以及非戒酒减少饮酒的好处。提供这个 他们的知识可以帮助他们改进筛查并对患者进行简短的干预。所以, 本行政补充文件的目标 2 是为医疗保健提供者准备一份文件,其中总结了 准确了解酗酒和酒精使用障碍的流行病学,以便 易于医疗保健提供者理解和使用。这项工作还将涉及意想不到的费用。

项目成果

期刊论文数量(12)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Heavy drinking among individuals with HIV: who drinks despite knowledge of the risk?
  • DOI:
    10.1080/09540121.2017.1382676
  • 发表时间:
    2018-05
  • 期刊:
  • 影响因子:
    1.7
  • 作者:
    Elliott JC;Stohl M;Hasin DS
  • 通讯作者:
    Hasin DS
Stability of Drinking Reductions and Long-term Functioning Among Patients with Alcohol Use Disorder.
  • DOI:
    10.1007/s11606-020-06331-x
  • 发表时间:
    2021-03
  • 期刊:
  • 影响因子:
    5.7
  • 作者:
    Witkiewitz K;Kranzler HR;Hallgren KA;Hasin DS;Aldridge AP;Zarkin GA;Mann KF;O'Malley SS;Anton RF
  • 通讯作者:
    Anton RF
The World Health Organization Risk Drinking Levels Measure of Alcohol Consumption: Prevalence and Health Correlates in Nationally Representative Surveys of U.S. Adults, 2001-2002 and 2012-2013.
  • DOI:
    10.1176/appi.ajp.2020.20050610
  • 发表时间:
    2021-06
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Shmulewitz D;Aharonovich E;Witkiewitz K;Anton RF;Kranzler HR;Scodes J;Mann KF;Wall MM;Hasin D;Alcohol Clinical Trials Initiative (ACTIVE Group)
  • 通讯作者:
    Alcohol Clinical Trials Initiative (ACTIVE Group)
World Health Organization risk drinking level reductions are associated with improved functioning and are sustained among patients with mild, moderate and severe alcohol dependence in clinical trials in the United States and United Kingdom.
  • DOI:
    10.1111/add.15011
  • 发表时间:
    2020-09
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Witkiewitz K;Heather N;Falk DE;Litten RZ;Hasin DS;Kranzler HR;Mann KF;O'Malley SS;Anton RF
  • 通讯作者:
    Anton RF
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DEBORAH S HASIN其他文献

DEBORAH S HASIN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DEBORAH S HASIN', 18)}}的其他基金

COVID-19, heavy drinking and alcohol use disorders: a national study of Veterans Administration patients
COVID-19、酗酒和酒精使用障碍:一项针对退伍军人管理局患者的全国研究
  • 批准号:
    10371482
  • 财政年份:
    2022
  • 资助金额:
    $ 1.59万
  • 项目类别:
COVID-19, heavy drinking and alcohol use disorders: a national study of Veterans Administration patients
COVID-19、酗酒和酒精使用障碍:一项针对退伍军人管理局患者的全国研究
  • 批准号:
    10596115
  • 财政年份:
    2022
  • 资助金额:
    $ 1.59万
  • 项目类别:
Scientific Conferences for The College on Problems of Drug Dependence (CPDD)
药物依赖问题学院科学会议(CPDD)
  • 批准号:
    10610865
  • 财政年份:
    2021
  • 资助金额:
    $ 1.59万
  • 项目类别:
Impact of Medical and Recreational Marijuana Laws On Cannabis, Opioids And Psychiatric Medications: National Study of VA Patients, 2000 - 2024
医用和娱乐大麻法对大麻、阿片类药物和精神药物的影响:2000 年至 2024 年退伍军人事务部患者的全国研究
  • 批准号:
    10393578
  • 财政年份:
    2019
  • 资助金额:
    $ 1.59万
  • 项目类别:
Impact of Medical and Recreational Marijuana Laws On Cannabis, Opioids And Psychiatric Medications: National Study of VA Patients, 2000 - 2024
医用和娱乐大麻法对大麻、阿片类药物和精神药物的影响:2000 年至 2024 年退伍军人事务部患者的全国研究
  • 批准号:
    10612385
  • 财政年份:
    2019
  • 资助金额:
    $ 1.59万
  • 项目类别:
Drinking levels (binge, volume) and alcohol consequences: using national data to identify clinical trial endpoints
饮酒水平(酗酒、饮酒量)和酒精后果:使用国家数据确定临床试验终点
  • 批准号:
    9440313
  • 财政年份:
    2016
  • 资助金额:
    $ 1.59万
  • 项目类别:
Drinking levels (binge, volume) and alcohol consequences: using national data to identify clinical trial endpoints
饮酒水平(酗酒、饮酒量)和酒精后果:使用国家数据确定临床试验终点
  • 批准号:
    9883624
  • 财政年份:
    2016
  • 资助金额:
    $ 1.59万
  • 项目类别:
HealthCall: Enhancing brief intervention for HIV primary care alcohol dependence
HealthCall:加强对艾滋病毒初级保健酒精依赖的短期干预
  • 批准号:
    9317400
  • 财政年份:
    2014
  • 资助金额:
    $ 1.59万
  • 项目类别:
HealthCall: Enhancing brief intervention for HIV primary care alcohol dependence
HealthCall:加强对艾滋病毒初级保健酒精依赖的短期干预
  • 批准号:
    8731034
  • 财政年份:
    2014
  • 资助金额:
    $ 1.59万
  • 项目类别:
HealthCall: Enhancing brief intervention for HIV primary care alcohol dependence
HealthCall:加强对艾滋病毒初级保健酒精依赖的短期干预
  • 批准号:
    8932642
  • 财政年份:
    2014
  • 资助金额:
    $ 1.59万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 1.59万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 1.59万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 1.59万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 1.59万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 1.59万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 1.59万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 1.59万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 1.59万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 1.59万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 1.59万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了